Reglan and Tardive Dyskinesia: What the FDA Adverse Event Reports Show

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Awareness to Occupational Risk

If you or someone you know has developed involuntary muscle movements after taking Reglan, you may be concerned about tardive dyskinesia. The historical recognition of such movement disorders from dopamine-blocking medications has shaped current monitoring protocols. This page reviews the FDA adverse event reports and what they reveal about diagnosis and long-term outlook.

The FDA Warning and Clinical Evidence

Reglan (metoclopramide) is a medication approved for specific gastrointestinal conditions, but its use carries a well-documented risk of causing tardive dyskinesia (TD), a potentially irreversible movement disorder. The U.S. Food and Drug Administration (FDA) has issued a boxed warning highlighting this risk, emphasizing that the likelihood of developing TD increases with longer treatment duration and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This warning is based on clinical evidence and postmarketing surveillance data. Tardive dyskinesia is characterized by involuntary, repetitive movements, often of the face, tongue, or extremities, which can be disfiguring and may persist even after the drug is discontinued (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The FDA-approved labeling for Reglan explicitly states that metoclopramide can cause TD and that the drug may suppress or partially mask the signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This masking effect is a critical concern because it can obscure the underlying disease process, leading to continued exposure and worsening of the condition.

Pharmacological Mechanism and Adverse Event Data

The pharmacological mechanism linking Reglan to TD involves metoclopramide's action as a dopamine receptor antagonist. By blocking dopamine receptors in the brain, particularly in the basal ganglia, metoclopramide can disrupt normal motor control pathways. Chronic blockade is thought to lead to upregulation of dopamine receptors, resulting in hypersensitivity and the abnormal involuntary movements characteristic of TD. This mechanistic pathway is consistent with the known effects of other dopamine-blocking agents that cause TD. The FDA Adverse Event Reporting System (FAERS) database provides substantial evidence of the association between Reglan and TD. As of the most recent data, there were 5,712 reports of tardive dyskinesia associated with Reglan, making it the most frequently reported adverse event for this drug (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:REGLAN). Other movement-related adverse events, such as extrapyramidal disorder (3,268 reports), dystonia (2,351 reports), and dyskinesia (779 reports), are also commonly reported, underscoring the neurological risks of the medication.

Causation and Risk Context

The adequacy of warnings regarding Reglan and TD has been a subject of regulatory attention. The boxed warning advises that Reglan is contraindicated in patients with a history of TD and that the drug should be used for the shortest duration necessary, with periodic reassessment of the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with diabetic gastroparesis, the maximum recommended treatment duration is 12 weeks, and longer-term use should be avoided if possible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, the high number of FAERS reports suggests that TD continues to occur, possibly due to prolonged use or inadequate monitoring. For affected patients, causation considerations are important. The development of TD after Reglan exposure is strongly supported by the temporal relationship between drug use and symptom onset, as well as the biological plausibility of the mechanism. The FDA labeling notes that the risk of TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Therefore, patients who have taken Reglan for extended periods or at high doses are at greater risk. The timeline between exposure and documented harm can vary; some patients may develop symptoms within weeks, while others may experience onset after months or years of use. Once TD develops, it may be irreversible, even after Reglan is discontinued. In summary, the evidence clearly establishes a causal link between Reglan and tardive dyskinesia, supported by pharmacological mechanisms, clinical warnings, and extensive adverse event reports. Healthcare providers and patients should be vigilant about the risks, adhere to recommended treatment durations, and monitor for early signs of TD to mitigate harm.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the FDA warning about Reglan and tardive dyskinesia?

The FDA has issued a boxed warning for Reglan (metoclopramide) stating that the drug can cause tardive dyskinesia (TD), a potentially irreversible movement disorder. The risk increases with longer treatment duration and higher cumulative doses. The warning advises using Reglan for the shortest duration necessary and contraindicates its use in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

How does Reglan cause tardive dyskinesia?

Reglan is a dopamine receptor antagonist. Chronic blockade of dopamine receptors in the brain, particularly in the basal ganglia, can lead to upregulation and hypersensitivity of these receptors, resulting in the abnormal involuntary movements characteristic of TD. This mechanism is similar to other dopamine-blocking agents known to cause TD.

What evidence supports the link between Reglan and tardive dyskinesia?

The FDA Adverse Event Reporting System (FAERS) has recorded 5,712 reports of tardive dyskinesia associated with Reglan, making it the most frequently reported adverse event for the drug. Additionally, the FDA labeling explicitly states the risk, and clinical studies support the temporal and biological plausibility of the link (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:REGLAN).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.